Skip to content

Platform
- Overview
- Publications and Presentations
Pipeline
- Overview
- Clinical Trials
About Us
Careers
News
Contact

Platform
- Overview
- Publications and Presentations
Pipeline
- Overview
- Clinical Trials
About Us
Careers
News
Contact

News

Read the latest news about our company.
To learn more about our research, visit our publications page.

See our publications

Year
Media Type
Search

January 7, 2025 | Press Release

Interius BioTherapeutics Announces Regulatory Approval to Expand Phase 1 Clinical Trial of INT2104 into Europe

November 26, 2024 | Media Coverage

pharmaphorum Podcast: CAR-T therapies: Faster, better, cheaper

November 25, 2024 | Media Coverage

BiotechTV: Philadelphia based Interius BioTherapeutics recently dosed the first patient for its in vivo CAR therapy that edits T and NK cells in the body so they target CD20 positive cells in B-cell malignancies

October 31, 2024 | Media Coverage

Philadelphia Business Journal: University of Pennsylvania gene therapy spinout Interius BioTherapeutics doses patient, achieves CAR therapy first

October 28, 2024 | Media Coverage

pharmaphorum: Viva in vivo: The next generation of cell therapy is fast approaching

October 23, 2024 | Press Release

Interius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies

12 3 4 5

Platform
- Overview
- Publications and Presentations
Pipeline
- Overview
- Clinical Trials
About Us
Careers
News
Contact

Platform
- Overview
- Publications and Presentations
Pipeline
- Overview
- Clinical Trials
About Us
Careers
News
Contact

Science

Platform
Pipeline
INT2104
INT2106
Publications
Clinical Trials

Company

About Us
Leadership
Board of Directors
Careers
Contact
News

Copyright © 2025 Interius BioTherapeutics, Inc. All Rights Reserved.
Interius^® is a registered trademark of Interius BioTherapeutics, Inc.

Accessibility
Cookies Notice
Privacy Notice
Terms of Use